With Perjeta, The Cost Of HER2 Breast Cancer Therapy Goes Up
Roche’s Perjeta will be priced at a premium to Herceptin and used in combination with it, more than doubling the cost of treating patients with HER2-positive metastatic breast cancer.
Roche’s Perjeta will be priced at a premium to Herceptin and used in combination with it, more than doubling the cost of treating patients with HER2-positive metastatic breast cancer.